Last reviewed · How we verify
Alternating chemotherapy
Alternating chemotherapy uses sequential administration of different chemotherapeutic agents to overcome drug resistance and improve treatment efficacy.
Alternating chemotherapy uses sequential administration of different chemotherapeutic agents to overcome drug resistance and improve treatment efficacy. Used for Acute leukemia (likely acute myeloid leukemia, based on PETHEMA Foundation focus).
At a glance
| Generic name | Alternating chemotherapy |
|---|---|
| Sponsor | PETHEMA Foundation |
| Drug class | Chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach involves rotating between distinct chemotherapy drugs with different mechanisms of action and resistance profiles, administered in alternating cycles. By switching agents, the regimen aims to prevent the development of cross-resistant tumor clones and maximize cytotoxic effect while potentially reducing cumulative toxicity from any single agent.
Approved indications
- Acute leukemia (likely acute myeloid leukemia, based on PETHEMA Foundation focus)
Common side effects
- Myelosuppression
- Infection
- Nausea and vomiting
- Mucositis
- Cardiotoxicity
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors (PHASE1, PHASE2)
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers (PHASE1, PHASE2)
- Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy (NA)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |